Atrial Fibrillation and Stroke Incidence
Atrial fibrillation (AFib) is a significant source of strokes that occur annually in the U.S.. Earlier identification of stroke risk is crucial for providers to intervene in a timely manner.
Advanced AFib-Stroke Detection
Reveal for Stroke utilizes existing ECG and electronic health record (EHR) data to provide personalized stroke-risk assessment for adults aged 22 and older. Our solution helps identify individuals with undiagnosed AFib or Atrial Flutter, and calculates their CHA2DS2-VASc score for stroke risk.
Reveal assists healthcare providers in making well-timed and informed decisions by presenting the FDA-cleared AccurECGTM analysis, stroke risk score, and the HAS-BLED score for major bleeding risk.
Discover how our solution supports proactive stroke prevention for better patient outcomes.
Reveal for Stroke Features
Impactful
Finds nearly 20% the patients at risk for stroke
Efficient
Presents a simple list of higher risk patients who should receive priority follow-ups
Integrated
Complements and enhances your existing clinical workflows
Secure
Proven data security with HIPAA compliance and SOC 2 certification
The Reveal Difference
Improves detection of AFib and Atrial Flutter by 19%, and surfaces 95% of previously unidentified AFib patients
Automatically highlights a short list of higher-risk patients from existing data based on CHA2DS2-VASc in 1000’s of existing records
Flags patients for outpatient appointment scheduling without creating new EHR clicks or bothersome alerts for providers
Enables timely preventive treatment for patients at risk, and supports care pathway selection by computing the HAS-BLED score
Helps organizations build sustaining outpatient CV service line volumes by identifying patients for preventive care
Relieves strain on hospital inpatient capacity by surfacing at-risk patients and enabling outpatient treatment
How It Works
See how Reveal early detection solutions and timely provider intervention can improve outcomes and quality of life for patients enabling treatment before a patient’s a condition may become more difficult and expensive to manage.
Impact of AFib-Related Stroke
According to the American Heart Association, AFib (atrial fibrillation) affects 2.7-6.1 million people in the US. AFib significantly increases the likelihood of having a stroke, with AFib-related strokes accounting for approximately 15-20% of all ischemic strokes.
By identifying patients at risk for stroke early on, the long-term use of blood thinners can reduce negative outcomes by 60-70%.
Despite this, studies consistently show that at least 1 in 5 cases of AFib go undocumented in clinical practice, which means many patients are not included in stroke prevention programs. This issue highlights the necessity for improved detection and management of AFib to ensure that all individuals at risk are identified and provided with appropriate care to minimize the potential for adverse health outcomes.
From Partners You Can Trust
Lucem Health partnered with AccurKardia to develop the Reveal for Stroke solution.
About AccurKardia
AccurKardia is an ECG-led diagnostics company that enables world-class cardiac care in a connected world. Their proprietary AccurECGTM Analysis System is an FDA-cleared and HIPAA-compliant, device-agnostic, fully automated ECG interpretation cloud-based software solution. AccurECGTM can detect 13 different arrhythmias with exceptional accuracy, thus helping healthcare organizations select enriched sub-populations and more consistently identify and prioritize patients for interventions for multiple cardiovascular conditions to halt or prevent serious complications from the onset of disease.
Detect More Stroke Risk, Do More Good
With Reveal for Stroke, you can harness the power of advanced detection to reveal hidden AFib-related stroke risks earlier, focus your clinical resources, and improve patient outcomes—without extensive training, adapting your clinical workflows, or undergoing extensive data and systems integration.
